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Background: Sleep disturbances are one of the main complaints of patients with trauma-related disorders. The
original Pittsburgh Sleep Quality Index Addendum for PTSD (PSQI-A) is self-report instrument developed to
evaluate posttraumatic stress disorder (PTSD)-specific sleep disturbances in trauma-exposed individuals.
However, to date, the PSQI-A has not yet been translated nor validated in French.
Objective: The present study aims to: a) translate the PSQI-A into French, and b) examine its psychometric
properties.
Method: Seventy-three adult patients (mean age 40.3 [SD 15.0], 75% females) evaluated in a specialized
psychotraumatology unit completed the French versions of the PSQI-A, Pittsburgh Sleep Quality Index
(PSQI), Hospital Anxiety and Depression Scale (HADS), and Impact Event Scale-Revised (IES-R).
Results: The French version of the PSQI-A showed satisfactory internal consistency, inter-item correlations,
item correlations with the total score, convergent validity with PTSD and anxiety measures, and divergent
validity with a depression measure.
Conclusion: Our findings support the use of the French version of the PSQI-A for both clinical care and
research. The French version of the PSQI-A is an important addition to the currently available instruments
that can be used to examine trauma-related sleep disturbances among French-speaking individuals.
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S
leep disturbances are common clinical problems
reported by patients with psychiatric conditions,
such as mood disorders, anxiety disorders, and
psychotic disorders. It is estimated that over 70% of
individuals with posttraumatic stress disorder (PTSD)
experience sleep disturbances (Ohayon & Shapiro, 2000).
Furthermore, sleep complaints are identified as a core
symptom of PTSD (Spoormaker & Montgomery, 2008)
and are suggested to be the hallmark of PTSD (Germain,
2013; Ross, Ball, Sullivan, & Caroff, 1989). A body of
evidence suggests that trauma-related sleep disturbances
reflect a central dysfunction that might contribute to
the maintaining and/or worsening of PTSD symptoms
(Babson & Feldner, 2010). For instance, sleep distur-
bances occurring after trauma exposure are associated
with an increased risk for PTSD (see Germain, Buysse, &
Nofzinger, 2008, for review; Mellman, Bustamante,
Fins, Pigeon, & Nolan, 2002) and comorbid depression
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However, trauma-related sleep disturbances are still
often considered as a secondary symptom of PTSD and
rarely assessed in clinical settings and may therefore be
underestimated (Krakow et al., 2001a; Spoormaker &
Montgomery, 2008).
The most commonly experienced trauma-related sleep
disturbances are nightmares and insomnia (Breslau et al.,
2004). Accordingly, these sleep symptoms are included
in both the re-experiencing (i.e., ‘‘recurrent distressing
dreams of the event’’) and hyperarousal (i.e., ‘‘difficulty
falling or staying asleep’’) DSM-IV-TR symptom clusters
(American Psychiatric Association, 2000). Other disrup-
tive nocturnal behaviors including night terrors, panic
attacks during sleep, bad dreams not related to the
trauma, and simple or complex motor behaviors during
sleep are also common in PTSD (Germain, Hall, Krakow,
Shear, & Buysse, 2005).
First-line psychotherapeutic interventions have been
found to be efficacious in reducing daytime PTSD
symptom severity. However, data suggest that they pro-
vide little to no benefit in reducing trauma-related sleep
disturbances (Germain, Shear, Hall, & Buysse, 2007).
For instance, it has been reported that almost 50% of
patients receiving cognitive behavioral therapy for PTSD
continue to experience residual sleep disturbances post-
treatment (Zayfert & DeViva, 2004). Pharmacological
treatments for PTSD have also been found efficacious
in reducing daytime PTSD symptoms but common side
effects include increased sleep disturbances (Babson &
Feldner, 2010; Mayers & Baldwin, 2005).
Pharmacological (Germain et al., 2012; Raskind et al.,
2007) and psychological sleep-focused interventions
(Forbes et al., 2003; Krakow et al., 2001b; Moore &
Krakow, 2010) have been shown to improve both
nocturnal and daytime PTSD symptoms concurrently
(e.g., Augedal, Hansen, Kronhaug, Harvey, & Pallesen,
2013; Escamilla, LaVoy, Moore, & Krakow, 2012). As
such, prazosin (an a-1 adrenergic antagonist) and ima-
gery rehearsal therapy (IRT) have been recommended
as the treatment of choice (level A) for posttraumatic
nightmares by the American Association Sleep Medicine
commissioned task force (Aurora et al., 2010). While
successful implementation and further examination of the
efficacy of these treatments are necessary worldwide, to
date, there are no instruments measuring trauma-related
sleep disturbances validated in French.
Several instruments have been developed to measure
sleep quality and sleep disturbances. The Pittsburgh Sleep
Quality Index (PSQI) is one of the most widely used
measurement instruments in clinical and research settings
and has been translated into 48 different languages
(Buysse et al., 2008). The PSQI was developed by Buysse
and colleagues in 1989 to measure subjective sleep quality
during the previous month. Although the PSQI assesses
seven sleep components, it does not measure PTSD-
specific sleep disturbances. For this purpose, the PSQI
Addendum for PTSD (PSQI-A) was introduced by
Germain and colleagues in 2005. The PSQI-A has good
psychometric properties, and a cutoff score of 4, exhibits
high sensitivity, specificity and a good positive predictive
value for discriminating between women (Germain et al.,
2005), as well as male military veterans (Insana, Hall,
Buysse, & Germain, 2013), with andwithout PTSD. Thus,
the PSQI-A provides a valid and clinically relevant
measure to assess posttrauma sleep disturbances. The
clinical usefulness of the PSQI-A has been recognized and
the instrument has therefore been translated into other
languages for broader dissemination, which includes
Persian for use in Iran (Farrahi, Nakhaee, Sheibani,
Garrusi, & Amirkafi, 2009).
However, to date, the PSQI-A has not yet been trans-
lated nor validated in French. Thus, this study aims to
translate the PSQI-A into French and subsequently
evaluate its psychometric properties. We hypothesized
that the French version of the PSQI-A would demons-
trate similar psychometric properties and validity com-
pared to the original English version.
Method
Participants
Seventy-three adult patients who were treated at the
Psychotraumatology Unit of Tenon University Hospital
(Paris, France) between October 2007 and September
2008 were recruited to participate in this study. Datawere
collected as part of our routine clinical care. Although
this research was not formally submitted to an ethics
committee, it was conducted in accordance with the
guidelines of the Helsinki declaration. All participants
provided verbal informed consent for use of their data
in this study. Participants were ]18 years old, French
speaking, had been previously exposed to traumatic
events, were free from psychotic or cognitive disorders,
and were hospitalized or receiving outpatient treatment.
Participants had anxiety or depression, with or without
PTSD symptoms and sleep disturbances.
PSQI-A translation
First, the original English version of the PSQI-A was
translated into French by L. Jehel, M. Ait-Aoudia, and
C. Stancu. Step one of the English-to-French transla-
tion procedure consisted of three translations of the
instrument followed by consensus agreement among the
translators.
Second, the French-translated PSQI-A was back-
translated into English by D. Morali, a bilingual psy-
chiatrist who was not familiar with the original English
version of the PSQI-A.
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back-translated French-to-English PSQI-A versions
were reviewed by a panel of professionals affiliated with
the Psychiatry Unit at Tenon University Hospital. The
panel consisted of professionals who were involved in
the first and second steps of the procedure, and others
who were naive to both the English- and French-
translated PSQI-A versions. At the end of this review,
only small changes were made to clarify and optimize the
French-translated PSQI-A. The final French version of
the PSQI-A (PSQI-A FV), as presented in Appendix,
was approved by several bilingual clinicians including A.
Germain, a co-creator and lead author of the original
(English) PSQI-A validation study.
Measures
The Pittsburgh Sleep Quality Index
The French version of the PSQI was used to assess sleep
qualityduring the past month (Blais, Gendron, Mimeault,
& Morin, 1997). The 19-item self-report PSQI evaluates
sevensleep components: (1) sleep quality, (2) sleep latency,
(3) sleep duration, (4) habitual sleep efficiency, (5) sleep
disturbance, (6) use of sleeping medication, and (7)
daytime dysfunction. Each of the seven components is
rated on a 0 3 scale. The total score resulting from the
sum of the seven components ranges from 0 to 21, and a
cut off  5 has been found to reflect clinically significant
sleep disturbances (Buysse, Reynolds, Monk, Berman, &
Kupfer, et al., 1989). The PSQI is one of the most
frequently used instruments to examine sleep for clinical
and research purposes (Buysse et al., 2008). The PSQI
was translated into French and validated in 1997 by Blais
and colleagues (Blais et al., 1997).
The Pittsburgh Sleep Quality Index Addendum
for PTSD
The PSQI-A was the first validated instrument intro-
duced to assess past-month sleep disturbances that are
specifically associated with PTSD (Germain et al., 2005).
The PSQI-A consists of seven items that estimate the
frequency of: (1) hot flashes; (2) general nervousness;
(3) memories or nightmares of a traumatic experience; (4)
anxiety or panic, not related to traumatic memories;
(5) bad dreams not related to traumatic memories; (6)
episodes of terror or screaming during sleep without fully
awakening; and (7) episodes of ‘‘acting out’’dreams, such
as kicking, punching, running or screaming. Each item
is rated on a Likert scale from 0 to 3 (0 not during the
past month,1  less than once a week,2 once or twice a
week,3  three or more times a week). A total score is
obtained from the sum of all seven items, and has a range
of 0 21. Three additional questions probing information
about anxiety, anger-accompanying memories or night-
mares of a traumatic experience (item 3), and timing
when these occur are also included but are not added to
the total score. The PSQI-A can be completed in less than
5 min.
The original PSQI-A validation study reported a
Cronbach’s coefficient a of 0.85 and a mean PSQI-A
item-total correlation of r 0.47. All item correlations
were statistically significant (pB0.001). The PSQI-A
showed moderate to strong positive correlations with the
Clinician-Administered PTSD Scale (r 0.53, pB0.007)
and the PTSD Symptom Scale (r 0.56, pB0.001). A
score ]4 yielded a sensitivityof 94%, a specificityof 82%,
and a positive predictive value of 93% to distinguish
individuals with PTSD from those without (Germain
et al., 2005).
Impact of Event Scale-Revised
The French version of the Impact of Event Scale-Revised
(IES-R) was used to evaluate PTSD symptoms during the
past 7 days (Brunet, St-Hilaire, Jehel, & King, 2003). The
22-item self-report IES-R measures symptoms of intru-
sion, avoidance, and hypervigilance (Weiss & Marmar,
1997). Each item is scored on a 0 4 point scale, with
higher scores reflecting increased PTSD symptom sever-
ity. The IES-R is a widely used instrument reported
across the international literature. The IES-R French
validation study reported good internal consistency with
a Cronbach’s a of 0.93 (Brunet et al., 2003). A cutoff
score of ]36 has been shown to indicate a level of PTSD
symptoms severity compatible with a PTSD diagnosis
(Jehel & Dayan, 2004).
Hospital Anxiety and Depression Scale
Participants were administered the French version of
the Hospital Anxiety and Depression Scale (HADS) to
evaluate depression and anxiety symptoms during the
past 7 days (Le ´pine, Godchau, & Brun, 1985). The
HADS scale includes 14 items, each of which is scored
on a 0 3 point Likert scale. Higher HADS total scores
indicate increased symptom severity (Zigmond & Snaith,
1983). Specific items can be separately summed to pro-
vide two 7-item subscales for depressive symptoms
(HADS-D) and anxiety symptoms (HADS-A), respec-
tively. The French version of the HADS demonstrated
satisfactory psychometric validity. Subscale scores ]10
are commonly used to indicate both anxiety and depres-
sion for the respective subscales (Le ´pine, 1996; Le ´pine
et al., 1985).
Procedure
Participants were assessed for PTSD symptoms (re-
expressing, avoidance, and hyperarousal clusters) with
the IES-R, and were classified into a probable PTSD
(IES-R]36) based on their total score. Participants also
completed the French-translated PSQI-A, PSQI, and
HADS.
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Quantitative variables were tested using Mann Whitney
tests and Spearman’s correlation coefficients. The internal
reliability of the French-translated PSQI-A calculated
with Cronbach’s coefficient a and test retest reliability
was assessed with Spearman’s correlation coefficient and
the intraclass correlation coefficient. Sensitivity, specifi-
city, and positive predictive value to identify probable
PTSD were computed with 95% confidence intervals
(CI). A receiver operating characteristic (ROC) analy-
sis was implemented. SPSS 17.0 and Statview 5.0 soft-
wares were used. The significance level was set to 0.05
(two-tailed).
Results
The total sample was composed of 73 participants. All
participants were exposed to at least one traumatic event
and were being treated for PTSD symptoms. Participants
had been suffering from PTSD symptoms for at least
2 months, with some for more than 10 years.
The sample included 57 participants who had IES-R
scores above the cutoff value of 36 (range: 37 84) and
16 participants below the cutoff value of 36 (IES-R
range: 0 35).
Patients with a score ]36 on the IES-R were classi-
fied in the probable PTSD group, while those who scored
B36 were classified in the no-PTSD group. Participants’
comorbid depression and anxiety, as well as medication
use, is indicated in Table 1.
The probable PTSD group (n 57) exhibited clinically
significantsleepdisturbances(PSQI:range;9 21),marked
trauma-related sleep disturbances (PSQI-A: range; 3 21),
and moderate to high levels of anxiety and depressive
symptoms. The no-PTSD group included 16 participants
who exhibited poor sleep quality and sleep disturbances
(PSQI: range; 2 17), some trauma-related sleep distur-
bance (PSQI-A: range; 2 13), and low to moderate levels
of anxiety and depressive symptoms. The no-PTSD group
scored significantly lower than the probable PTSD group
on the global scores for all measures (all pB0.05).
Descriptive statistics and comparisons between the two
groups are reported in Table 2.
Psychometric properties of the French version of
PSQI-A
Internal consistency
The PSQI-A FV demonstrated adequate internal consis-
tency with a 0.72. Correlations between each PSQI-A
FV items and the total PSQI-A FV score ranged from
r 0.52 to r 0.67, pB0.0001 (Table 2).
Convergent and divergent validity
The PSQI-A FV demonstrated convergent validity with
both PTSD and anxiety symptoms. The PSQI-A FV was
associated with the IES-R total score, IES-R total score
after removing the three sleep items (items: 2. waking at
night, 5. trouble falling asleep, and 20. nightmares), and
the HADS-A. The PSQI-A FV demonstrated divergent
validity with depression symptoms. The PSQI-A FV was
not associated with the HADS-D, r 0.04, p 0.71
(Table 2).
Sensitivity, specificity, and positive predictive value
In order to optimize the PSQI-A FV for application as
a screening tool for adult patients who are most likely
Table 1. Sociodemographic and clinical characteristics of 73 trauma exposed treatment-seeking adult patients with and without
probable PTSD
Total sample N 73 Probable PTSD group n 57 No-PTSD group n 16
Mean age years M 40.3 (SD 15) M 39.2 (SD 14.3) M 44.2 (SD 17.2)
Gender
Female 55 (75%) 45 (79%) 12 (75%)
Male 18 (25%) 12 (21%) 4 (25%)
Depression*
Yes 45 (62%) 37 (65%) 8 (50%)
No 28 (38%) 20 (35%) 8 (50%)
Anxiety*
Yes 62 (85%) 54 (95%) 8 (50%)
No 11 (15%) 03 (5%) 8 (50%)
Sleep medication use
Yes 48 (66%) 41 (72%) 7 (44%)
No 25 (34%) 16 (28%) 9 (56%)
*Participants with total scores ]10 (cutoff) on each subscales HADS-A: Anxiety state-Hospital Anxiety and Depression Scale and
Depression state; HADS-D: Anxiety state-Hospital Anxiety and Depression Scale.
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score was calculated to provide the highest sensitivity and
strongest positive predictive value (Fig. 1). The area
below the ROC curve was 0.81, showing an 81% pro-
bability that a randomly selected probable PTSD patient
would have a higher PSQI-A FV score than a randomly
selected no-PTSD patient. The ROC analysis also showed
that a PSQI-A FV total score]6 would provide 87%
sensitivity and 50% specificity (95% CI 79 95 and 39 61,
respectively). A score ]6 showed 86% positive and 53%
negative predictive value (95% CI 78 94 and 42 64,
respectively).
Test retest reliability
The temporal stability of the PSQI-A FV was examined
at 7-day intervals. Thirty-five patients were selected to
complete the PSQI-A twice within that period, but data
for only 28 patients out of the 35 were available for test 
retest analyses, as seven participants did not complete the
retest. Among these participants, the PSQI-A FV scores
demonstrated satisfactory temporal stability, r 0.74
(pB0.0001) and intraclass correlation coefficient 0.76.
Discussion
This study describes the translation of the PSQI-A to
French and reports on the psychometric properties for
use among French-speaking individuals. As expected,
similar to the original PSQI-A, the PSQI-A FV demon-
strated satisfactory internal reliability (a 0.85, a 0.72,
respectively) and strong positive correlations between
each item and the total score. The PSQI-A FV had good
convergent validity with measures of sleep quality as
measured by the PSQI. These results indicate that the
PSQI-A FV items represent related aspects of a single
underlying construct of sleep disturbance.
Table 2. Relationship between PSQI-AFV items, clinical symptoms and probable PTSD status among 73 trauma-exposed
treatment-seeking adult patients
Probable PTSD group (n 57) No-PTSD group (n 16) Total sample (N 73)
M (SD) M (SD) p* Total PSQI-A score r** p**
IES-R 62.25 (11.82) 21.06 (12.62) B0.0001 0.60 B0.0001
IES-R (without 3 items related to sleep)      0.58 B0.0001
HADS-A 15.51 (3.29) 10.44 (3.69) B0.0001 0.48 B0.0001
HADS-D 11.68 (4.02) 8.50 (5.09) 0.02 0.04 0.71
Total PSQI score 15.02 (3.36) 9.44 (4.10) B0.0001 0.55 B0.0001
Total PSQI-A score 11.77 (4.65) 6.57 (3.37) 0.0001   
Hot flashes 1.38 (1.32) 0.75 (0.86) 0.09 0.57 B0.0001
General nervousness 2.47 (0.85) 1.26 (0.89) 0.0006 0.52 B0.0001
Memories/nightmares of trauma 2.14 (1.06) 1.31 (1.13) 0.009 0.60 B0.0001
Anxiety/panic not related to trauma 1.79 (1.19) 0.81 (0.99) 0.004 0.67 B0.0001
Bad dreams not related to trauma 1.44 (1.13) 1.06 (1.18) 0.22 0.57 B0.0001
Episodes of terror 1.21 (1.17) 0.44 (0.73) 0.01 0.68 B0.0001
Acting out dreams 1.33 (1.23) 0.56 (0.96) 0.02 0.63 B0.0001
Note. PSQI: Pittsburgh Sleep Quality Index; PSQI-A: Pittsburgh Sleep Quality Index-Addendum; HADS-A: Anxiety state-Hospital
Anxiety and Depression Scale; Depression state- HADS-D: Anxiety state-Hospital Anxiety and Depression Scale; IES-R: Impact Event
Scale-Revised, without 3 items related to sleep: item 2: waking at night; item 15: trouble falling asleep; item 20: nightmares.
*Mann Whitney tests; **Spearman’s r test correlations.
Fig. 1. ROC curve presenting the power of the French
version of the PSQI-A to discriminate between probable
PTSD and no-PTSD using among 73 trauma-exposed
treatment-seeking individuals.
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version of the PSQI-A demonstrated good convergent
validity with measures of PTSD symptom severity
(r 0.60, pB0.001). Additionally, the probable PTSD
group demonstrated a significantly higher PSQI-A FV
total scores that the no-PTSD group. Thus, the PSQI-A
FV total score discriminated between the probable PTSD
and the no-PTSD groups, although some individuals in
the no-PTSD group reported some PTSD symptoms and
some PTSD sleep disturbances (see Table 2). Moreover,
the correlation between the PSQI-A FV and the IES-R
total score was significant even when IES-R sleep-related
items were removed (r 0.58, pB0.001). This result sug-
gests that the relationship between diurnal and nocturnal
PTSD symptoms may be detected by the PSQI-A FV is
further supported by the ROC analysis. The PSQI-A FV
had an 81% ability to differentiate patients with probable
PTSD from no-PTSD patients and appears to be an
adequate screening instrument for probable PTSD. A
PSQI-A FV score ]6 had good sensitivity and accurately
identified 87% of patients. However, the specificity of the
PSQI-A FV (50%) was acceptable, albeit moderate.
Additionally, 87% of patients scoring ]6 on the PSQI-
A FV total score had a probable PTSD yielding a false-
positive rate of 13%. Although the cutoff score of ]6i s
higher than the cutoff score identified in the original
PSQI-A validation study (]4), the higher cutoff score
identified in this study is also probably due to the
different patient populations from the original study.
Nevertheless, we recommend the original threshold score
of 4 even when using the PSQI-A FV. This score pro-
vides a lower threshold and greater screening sensiti-
vity to identify probable PTSD. The PSQI-A FV also
demonstrated good divergent validity with a measure
of depression. This suggests that PSQI-A FV is able
to discriminate between dimensions of PTSD and
depression.
In the original PSQI-Avalidation study, the total score
did not change over 6 months in healthy controls group,
whereas the PTSD group showed a significant reduction
in the PSQI-A total score at 6 months. Our results
suggest that the PSQI-A FV has good temporal stability
across a short time interval. Although a 7-day interval
was adequate to examine temporal stability, a longer
interval would provide a more robust temporal stability
assessment. Greater further analysis of sensitivity to
therapeutic change would provide important information
for future users of this instrument.
This preliminary study has other limitations. The
sample size of this study is relatively small and our
sample was composed of traumatized individuals, mostly
women, who were undergoing treatment in a psychotrau-
matology unit. Therefore, our findings should be con-
sidered in the context of this specific sample and
may not be generalized to a wider population. Further
instrument examination of the psychometric properties of
the PSQI-A FV in community-based samples, as well as
among individuals undergoing trauma-focused treatment
in various medical or mental health care settings, or
individuals with other psychiatric conditions are there-
fore warranted. Despite these limitations, given that
PTSD-related sleep problems pose therapeutic challenges
(e.g., Davis & Wright, 2007; Krakow et al., 2001a, 2001c),
these findings have both clinical and research implica-
tions. Within clinical settings, the PSQI-A FV is a valid
tool to assess posttraumatic sleep disturbances among
French-speaking individuals. Within research settings,
the PSQI-A FV may be used to better understand the
relationship between sleep and PTSD.
Conclusion
The PSQI-A FV is a self-administered questionnaire that
can be completed in five minutes and offers clinicians
a reliable way to screen adult patients who suffer from
PTSDsleepdisturbances.Ourstudydemonstratedthatthe
PSQI-A FV has satisfactory psychometric properties
amongFrancophoneadultpatientswhowerebeingtreated
for PTSD. Thus, the PSQI-A FV is a reliable tool, which
canbeused toexamineposttraumasleep disturbances and
to screen for probable PTSD among trauma-exposed
individuals. The validity of this instrument enables its use
for both clinical and research applications. A validated
version of the PSQI-A is now available for administration
to French-speaking individuals.
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(page number not for citation purpose)a) avez e ´prouve ´ des bouffe ´es de chaleur:
Jamais durant le dernier mois
I0
Moins d’une fois par semaine
I1
Une ou deux fois par semaine
I2
Trois fois ou plus par semaine
I3
Score –
b) ressentiez une nervosite ´g e ´ne ´rale:
Jamais durant le dernier mois
I0
Moins d’une fois par semaine
I1
Une ou deux fois par semaine
I2
Trois fois ou plus par semaine
I3
Score –
c) avez eu des souvenirs ou des cauchemars se rattachant a `u ne ´ve ´nement traumatique:
Jamais durant le dernier mois
I0
Moins d’une fois par semaine
I1
Une ou deux fois par semaine
I2
Trois fois ou plus par semaine
I3
Score –
d) avez e ´prouve ´ une anxie ´te ´s e ´ve `re ou de la panique qui n’e ´taient pas relie ´es a ` un souvenir traumatique:
Jamais durant le dernier mois
I0
Moins d’une fois par semaine
I1
Une ou deux fois par semaine
I2
Trois fois ou plus par semaine
I3
Score –
e) avez fait de mauvais re ˆves qui n’e ´taient pas relie ´s a ` des souvenirs traumatiques:
Jamais durant le dernier mois
I0
Moins d’une fois par semaine
I1
Une ou deux fois par semaine
I2
Trois fois ou plus par semaine
I3
Score –
f) avez eu des e ´pisodes de terreur ou de hurlements durant votre sommeil sans vous re ´veiller comple `tement:
Jamais durant le dernier mois
I0
Moins d’une fois par semaine
I1
Une ou deux fois par semaine
I2
Trois fois ou plus par semaine
I3
Score –
g) avez eu des e ´pisodes «d’action» pendant vos re ˆves, tels que donner des coups de pied, des coups de poing, courir ou crier:
Jamais durant le dernier mois
I0
Moins d’une fois par semaine
I1
Une ou deux fois par semaine
I2
Trois fois ou plus par semaine
I3
Score –
2. Si vous avez eu des souvenirs ou des cauchemars lie ´s a `u ne ´ve ´nement traumatique au cours de votre sommeil (question
1-c ci-haut)...
a) A ` quel point avez-vous ressenti de l’anxie ´te ´ durant ces souvenirs/cauchemars?
aucunement I0 Tre `s peu I1 moyennement I2 beaucoup I3 Score –
b) A ` quel point avez-vous ressenti de la cole `re durant ces souvenirs/cauchemars?
aucunement I0 Tre `s peu I1 moyennement I2 beaucoup I3 Score –
c) A ` quel moment de la nuit la plupart de ces souvenirs/cauchemars se sont-ils produits?
To ˆt dans la nuit I0 Dans le milieu de la nuit I1 Tard la nuit, pre `sdumatinI2 Pas de moment en particulier I3 Score –
Appendix
PSQI-A pour l’e ´valuation des troubles du sommeil posttraumatiques
A. Germain, M. Hall, B. Krakow, M. K. Shear, D. J. Buysse,
Adaptation version franc ¸aise L. Jehel, M. Ait Aoudia
N o m:________________P r e ´ n o m( s ):____________D a t e:__ /__ / __
CONSIGNES: Veuillez s’il-vous-plaı ˆt re ´pondre aux questions suivantes concernant votre sommeil au cours du
dernier mois. Ajoutez toute observation provenant de votre partenaire de chambre ou de lit.
1. Au cours du dernier mois, combien de fois avez-vous eu de la difficulte ´a ` dormir parce que vous ...
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